Vanessa Vizcaino, MD
Family Medicine · Wellington, FLNPI 1295797140
Payments from drug & device makers
Across 390 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$932
- Novo Nordisk$900
- AbbVie$832
- Pfizer$788
- Boehringer Ingelheim$409
- Lilly USA, LLC$366
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,706100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $932 |
| Novo Nordisk | 57 | $900 |
| AbbVie(2 entities) | 52 | $832 |
| Pfizer | 40 | $788 |
| Boehringer Ingelheim | 22 | $409 |
| Lilly USA, LLC | 26 | $366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $233 |
| Sanofi-aventis U.S. LLC | 10 | $208 |
| Merck | 15 | $207 |
| Amgen(2 entities) | 12 | $183 |
| Antares Pharma, Inc. | 7 | $139 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $132 |
| Abbott | 6 | $117 |
| Kowa Pharmaceuticals America, Inc. | 7 | $114 |
| Bayer | 4 | $106 |
| Endo Pharmaceuticals Inc. | 5 | $106 |
| GSK | 6 | $100 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 6 | $83 |
| Biohaven Pharmaceuticals, Inc. | 4 | $80 |
| Kvk-tech, Inc. | 1 | $62 |
| Amarin Pharma, Inc. | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Currax Pharmaceuticals LLC | 3 | $41 |
| Johnson & Johnson | 2 | $40 |
| Corcept Therapeutics | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Nalpropion Pharmaceuticals LLC | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $26 |
| Bausch Health US, LLC | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $21 |
| Medicure Pharma Inc. | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $13 |
How this compares
$6,706 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 66 | $80,378 |
| OzempicSemaglutide | 31 | $45,410 |
| JardianceEmpagliflozin | 29 | $41,317 |
| EliquisApixaban | 42 | $35,446 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $23,514 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $21,396 |
| JanuviaSitagliptin Phosphate | 12 | $19,012 |
| RybelsusSemaglutide | 14 | $13,344 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $11,773 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $8,224 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,654 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,074 |
| FarxigaDapagliflozin Propanediol | 11 | $4,996 |
| SynthroidLevothyroxine Sodium | 50 | $4,147 |
| DexilantDexlansoprazole | 12 | $3,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $366 | $80,37866 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $409 | $61,31372 claims |
| Novo NordiskOzempic, Rybelsus | $900 | $58,75445 claims |
| MerckJanumet Xr, Januvia | $207 | $42,52532 claims |
| PfizerEliquis | $788 | $35,44642 claims |
| GSKBreo Ellipta | $100 | $6,65417 claims |
| AstraZenecaFarxiga | $932 | $4,99611 claims |
| AbbVieSynthroid | $832 | $4,14750 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $233 | $3,55912 claims |
| Sanofi-aventis U.S. LLCLantus | $208 | $1,48712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Wellington
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.